KPV (Lys-Pro-Val) — tripeptide anti-inflammatory fragment
In short
Tripeptide fragment of α-MSH studied for anti-inflammatory activity via inhibition of the NF-κB pathway in tissue models.
Overview
KPV is the smallest known α-MSH-derived peptide that retains anti-inflammatory activity. The three-residue sequence (Lys-Pro-Val) corresponds to the C-terminus of α-MSH and engages melanocortin signaling along with MC1R-independent intracellular pathways. Its compact structure resists proteolytic degradation in the gut lumen — a property exploited in oral research formulations targeting intestinal inflammation.
KPV downregulates NF-κB activation in inflamed enterocytes and macrophages, reducing TNF-α, IL-6, and IL-1β output. The peptide also enters cells through PEPT1 transporter and modulates intracellular signaling independent of cell-surface MC1R, broadening its anti-inflammatory reach.
Molecular information
Amino-acid sequence
H-Lys-Pro-Val-OH
First-order decay curve at 0.5h half-life from literature. Educational only.
Нежеланите събития в публикуваните изследвания са минимални. Пептидът е малък, добре поносим и липсва сигнализационна промискуитетност при типични изследователски дози. Пигментационни ефекти (известен α-MSH class сигнал при по-високо MC1R активиране) не са съобщавани с KPV при изследователски дози.
3 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Information about KPV is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
